|
Feb 2
|
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
|
|
Feb 1
|
HUTCHMED to Announce 2023 Final Results
|
|
Jan 30
|
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
|
|
Jan 11
|
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
|
|
Dec 13
|
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
|
|
Dec 13
|
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
|
|
Dec 1
|
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
|
|
Nov 10
|
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
|
|
Nov 9
|
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
|
|
Aug 3
|
HUTCHMED (China) First Half 2023 Earnings: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)
|